Vivoryon Therapeutics N.V. (VVYN.VI)
Vienna · EUR · Healthcare · Biotechnology
€0.832 (-2.12%) as of
Key statistics
- Market cap
- 24.64M
- EPS (TTM)
- -0.2300
- Dividend yield
- 0.00%
- 52-week range
- 0.8320 – 1.6620
- Beta
- 1.40
- Profit margin
- 0.00%
About Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. operates as a clinical stage biopharmaceutical company that focuses on research, development, and commercialize small molecule-based medicines. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company's lead product candidate is PQ912, a nanomolar QPCT inhibitor that has completed Phase IIb clinical trials for use in the treatment of Alzheimer's disease. In addition, the company is developing a monoclonal antibody PBD-C06 is for N3pE-Abeta. Vivoryon Therapeutics N.V. has a collaboration agreement with Nordic Bioscience for the clinical development of PQ912 for Alzheimer's disease; and research collaboration with the Fraunhofer Institute for cell therapy and immunology, as well as a strategic regional licensing partnership with Simcere Pharmaceutical Group Ltd. to develop and commercialize medicines targeting the neurotoxic amyloid species N3pE (pGlu-Abeta) to treat Alzheimer's disease. The company was founded in 1997 and is based in Halle, Germany.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Halle, Germany
- Employees
- 13
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.